AbbVie (ABBV) EBIT (QoQ) (2012 - 2026)
Powered by 
Analysis
AbbVie (ABBV) EBIT (QoQ) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn |
| 2 | AbbVie | 446.28 Bn | 439.71 Bn | 12.70 Bn |
| 3 | Merck | 357.56 Bn | 350.42 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.11 Bn | 260.42 Bn | 11.24 Bn |
| 5 | Pfizer | 156.86 Bn | 145.17 Bn | 10.94 Bn |
| 6 | Sanofi | 52.10 Bn | 44.72 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.01 Bn | 43.01 Bn | - |
| 8 | Incyte | 24.82 Bn | 20.28 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.39 Bn | 18.73 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.92 Bn | 15.53 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.20% |
| Mar 31, 2026 | -12.19% |
| Dec 31, 2025 | 138.66% |
| Sep 30, 2025 | -61.10% |
| Jun 30, 2025 | 31.10% |
| Mar 31, 2025 | 350.54% |
| Dec 31, 2024 | -138.89% |
| Sep 30, 2024 | -4.18% |
| Jun 30, 2024 | 42.89% |
| Mar 31, 2024 | -12.43% |
| Dec 31, 2023 | 40.07% |
| Sep 30, 2023 | -49.46% |
| Jun 30, 2023 | 63.04% |
| Mar 31, 2023 | -49.69% |
| Dec 31, 2022 | 19.53% |
| Sep 30, 2022 | 39.70% |
| Jun 30, 2022 | -30.15% |
| Mar 31, 2022 | -7.04% |
| Dec 31, 2021 | 17.84% |
| Sep 30, 2021 | -3.04% |